A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Name: A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Published: 2024
License: Public Domain

BeOne Medicines · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

celllungcancer small

metastatic solid tumors, advanced non-squamous non-small-cell lung cancer, advanced colorectal cancer, advanced pancreatic ductal adenocarcinoma, advanced gastric cancer, advanced gastroesophageal junction cancer, advanced esophageal adenocarcinoma, kras wild type amplification, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Related documents